Publications by authors named "Masato Yabuki"

Claim this Profile
G
Gene Signature-Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn's Disease.
Kanae Gamo, Yuumi Okuzono, Masato Yabuki, Takashi Ochi, Kyoko Sugimura

Inflamm Bowel Dis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy.
Akira Shibata, Masako Kuno, Ryutaro Adachi, Yosuke Sato, Harumi Hattori, Masato Yabuki

PLoS One· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
Yoshinori Ishikawa, Kanae Gamo, Masato Yabuki, Shinji Takagi, Kosei Toyoshima

Mol Cancer Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924).
Hiroyuki Sumi, Masakazu Inazuka, Megumi Morimoto, Ryosuke Hibino, Kentaro Hashimoto, Masato Yabuki

Biochem Biophys Res Commun· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-3256336, a novel and orally available small molecule IAP antagonist, induced tumor cell death via induction of systemic TNF alpha production.
Hiroyuki Sumi, Masakazu Inazuka, Kentaro Hashimoto, Tomoyasu Ishikawa, Sei Yoshida, Masato Yabuki

Biochem Biophys Res Commun· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological activities of novel hexahydropyrazino[1,2-a]indole derivatives as potent inhibitors of apoptosis (IAP) proteins antagonists with improved membrane permeability across MDR1 expressing cells.
Zenyu Shiokawa, Kentaro Hashimoto, Bunnai Saito, Yuya Oguro, Hiroyuki Sumi, Masato Yabuki

Bioorg Med Chem· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, stereoselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonists.
Moriteru Asano, Kentaro Hashimoto, Bunnai Saito, Zenyu Shiokawa, Hiroyuki Sumi, Masato Yabuki

Bioorg Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives.
Masanori Okaniwa, Masaaki Hirose, Takeo Arita, Masato Yabuki, Akito Nakamura

J Med Chem· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity and pharmacodynamic biomarkers of a novel and orally available small-molecule antagonist of inhibitor of apoptosis proteins.
Hiroyuki Sumi, Masato Yabuki, Kenichi Iwai, Megumi Morimoto, Ryosuke Hibino

Mol Cancer Ther· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of potent inhibitor of apoptosis (IAP) proteins antagonists bearing an octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline mimetic.
Kentaro Hashimoto, Bunnai Saito, Naoki Miyamoto, Yuya Oguro, Daisuke Tomita, Masato Yabuki

J Med Chem· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives.
Masaaki Hirose, Masanori Okaniwa, Tohru Miyazaki, Takashi Imada, Tomohiro Ohashi, Masato Yabuki

Bioorg Med Chem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption.
Masanori Okaniwa, Takashi Imada, Tomohiro Ohashi, Tohru Miyazaki, Takeo Arita, Masato Yabuki

Bioorg Med Chem· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds.
Masanori Okaniwa, Masaaki Hirose, Takashi Imada, Tomohiro Ohashi, Youko Hayashi, Masato Yabuki

J Med Chem· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Ser46 phosphorylation of p53 is not always sufficient to induce apoptosis: multiple mechanisms of regulation of p53-dependent apoptosis.
Akira Kurihara, Hirokazu Nagoshi, Masato Yabuki, Ryuhei Okuyama, Masuo Obinata

Genes Cells· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis